1) Testosterone dose-response relationships in healthy young men. Bhasin S, et al. Am J Physiol Endocrinol Metab. 2001 Dec;281(6):E1172-81.
2) Dose-dependent effects of testosterone on regional adipose tissue distribution in healthy young men. Woodhouse LJ, et al. J Clin Endocrinol Metab. 2004 Feb;89(2):718-26.
3) Testosterone Threshold Levels and Lean Tissue Mass Targets Needed to Enhance Skeletal Muscle Strength and Function: The HORMA Trial. Sattler, F et al. J Gerontol A Biol Sci Med Sci. 2011 Jan;66(1):122-9.
4) Conversion of androsterone ester to dihydrotestosterone (DHT) -- with 10 hour pharmacokinetics Draws performed by AnyLabTestNow, 714 SW Washington St, Portland, OR 97205 , July 2011. Analysis performed by S.E.D. Medical Laboratories. (Contact Primordial Performance for full report)
5) In vivo conversion of dehydroisoandrosterone to plasma androstenedione and testosterone in man. Horton R, et al. J Clin Endocrinol Metab. 1967 Jan;27(1):79-88.
6) In vitro metabolism of androgens in whole human blood. Blaquier et al. Acta Endocrinol (Copenh). 1967 Aug;55(4):697-704. No abstract available.
7) METABOLISM OF ANDROST-4-ENE-3,17-DIONE-4-14C BY RABBIT SKELETAL MUSCLE SUPERNATANT FRACTION. ISOLATION OF 3BETA-HYDROXYANDROST-4-EN-17-ONE-14C AND TESTOSTERONE-14C. THOMAS et al. J Biol Chem. 1964 Mar;239:766-72. No abstract available
8) Direct agonist/antagonist functions of dehydroepiandrosterone. Chen et al. Endocrinology. 2005 Nov; 146(11):4568-76. Epub 2005 Jun 30
9) Serum androgen bioactivity during 5alpha-dihydrotestosterone treatment in elderly men. Raivio et al. J Androl. 2002 Nov-Dec;23(6):919-21.
10) In vitro bioassays for androgens and their diagnostic applications. Roy et al. Hum Reprod Update. 2008 Jan-Feb;14(1):73-82. Epub 2007 Dec 4.
11) Determination of androgen bioactivity in human serum samples using a recombinant cell based in vitro bioassay. Roy et al. J Steroid Biochem Mol Biol. 2006 Sep; 101(1):68-77. Epub 2006 Aug 8.
12) Circulating bioactive androgens in midlife women. Chen et al. J Clin Endocrinol Metab. 2006 Nov;91(11):4387-94. Epub 2006 Aug 29.
13) Partial agonist/antagonist properties of androstenedione and 4-androsten-3beta,17beta-diol. Chen Fet al. J Steroid Biochem Mol Biol. 2004 Aug;91(4-5):247-57.
14) Delta-4-androstene-3,17-dione binds androgen receptor, promotes myogenesis in vitro, and increases serum testosterone levels, fat-free mass, and muscle strength in hypogonadal men. Jasuja R, et al. J Clin Endocrinol Metab. 2005 Feb;90(2):855-63. Epub 2004 Nov 2.
15) Correlates of low testosterone and symptomatic androgen deficiency in a population-based sample. Hall SA, et al. J Clin Endocrinol Metab. 2008 Oct;93(10):3870-7. Epub 2008 Jul 29.
16) Two emerging concepts for elite athletes: the short-term effects of testosterone and cortisol on the neuromuscular system and the dose-response training role of these endogenous hormones. Crewther BT, et al. Sports Med. 2011 Feb 1;41(2):103-23. doi: 10.2165/11539170-000000000-00000.
17) Effect of oral androstenedione on serum testosterone and adaptations to resistance training in young men: a randomized controlled trial. King DS, et al. JAMA. 1999 Jun 2;281(21):2020-8.
18) Effects of anabolic precursors on serum testosterone concentrations and adaptations to resistance training in young men. Brown GA, et al. Int J Sport Nutr Exerc Metab. 2000 Sep;10(3):340-59.
19) Anticonvulsant activity of androsterone and etiocholanolone. Kaminski RM, et al. Epilepsia. 2005 Jun;46(6):819-27.
20) Definition of androgens and protein anabolic steroids. Kochakian CD. Pharmacol Ther B. 1975;1(2):149-77. Review. No abstract available.
21) The role of non-aromatizable testosterone metabolite in metabolic pathways. Du?ková M, et al. Physiol Res. 2011 May 10;60(2):253-61. Epub 2010 Nov 29.
22) Recruitment of the androgen receptor via serum response factor facilitates expression of a myogenic gene. Vlahopoulos S, et al. J Biol Chem. 2005 Mar 4;280(9):7786-92. Epub 2004 Dec 28.
23) Androgen-mediated improvement of body composition and muscle function involves a novel early transcriptional program including IGF1, mechano growth factor, and induction of {beta}-catenin. Gentile, M.A. et al. J. Mol. Endocrinol. 44, 55-73 (2010)
24) Stimulation of both estrogen and androgen receptors maintains skeletal muscle mass in gonadectomized male mice but mainly via different pathways. Svensson J, et al. J Mol Endocrinol. 2010 Jul;45(1):45-57. Epub 2010 Apr 30.
25) Body composition and anthropometry in bodybuilders: regional changes due to nandrolone decanoate administration. Hartgens F, et al. Int J Sports Med. 2001 Apr;22(3):235-41.
26) Comparison of the effects of high dose testosterone and 19-nortestosterone to a replacement dose of testosterone on strength and body composition in normal men. Friedl KE, et al. J Steroid Biochem Mol Biol. 1991;40(4-6):607-12.
27) Breaking the vicious circle of obesity: the metabolic syndrome and low testosterone by administration of testosterone to a young man with morbid obesity. Tishova Y, et al. Arq Bras Endocrinol Metabol. 2009 Nov;53(8):1047-51.
28) Testosterone Threshold Levels and Lean Tissue Mass Targets Needed to Enhance Skeletal Muscle Strength and Function: The HORMA Trial. Sattler, F et al. J Gerontol A Biol Sci Med Sci. 2011 Jan;66(1):122-9.
29) Androstenedione does not stimulate muscle protein anabolism in young healthy men. Rasmussen BB, et al. J Clin Endocrinol Metab. 2000 Jan;85(1):55-9.
30) The male climacterium: clinical signs and symptoms of a changing endocrine environment. van den Beld AW, et al. Prostate Suppl. 2000;10:2-8.
31) Testosterone dose-response relationships in healthy young men. Bhasin S, et al. Am J Physiol Endocrinol Metab. 2001 Dec;281(6):E1172-81.
32) Correlates of low testosterone and symptomatic androgen deficiency in a population-based sample. Hall SA, et al. J Clin Endocrinol Metab. 2008 Oct;93(10):3870-7. Epub 2008 Jul 29.
33) Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. Wu FC, et al. J Clin Endocrinol Metab. 2008 Jul;93(7):2737-45. Epub 2008 Feb 12.
34) Prevalence of and risk factors for androgen deficiency in middle-aged men in Hong Kong. Wong SY, et al. Metabolism. 2006 Nov;55(11):1488-94.
35) Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly men. van den Beld AW, et al. J Clin Endocrinol Metab. 2000 Sep;85(9):3276-82.
36) Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. Wu FC, et al. J Clin Endocrinol Metab. 2008 Jul;93(7):2737-45. Epub 2008 Feb 12.
37) Effects of anabolic steroids on the muscle cells of strength-trained athletes. Kadi F, et al. Med Sci Sports Exerc 31:1528-1534. (1999)
38) Testosterone-induced increase in muscle size in healthy young men is associated with muscle ber hypertrophy. Sinha-Hikim I, et al. Am J Physiol Endocrinol Metab 283:E154-E164 (2002)
39) Myonuclei acquired by overload exercise precede hypertrophyand are not lost on detraining. Bruusgaard JC. et al. Proc Natl Acad Sci U S A. 2010 Aug 24;107(34):15111-6. Epub 2010 Aug 16.
40) Strength Training and Anabolic Steroids Anders Eriksson, et al. University Medical Dissertations (2006)
41) In vivo MRI evaluation of anabolic steroid precursor growth effects in a guinea pig model. Tang H, et al Steroids. 2009 Aug;74(8):684-93. Epub 2009 Mar 20.